BioPharma Drug Approval
IASO Biotechnology ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therap...
July 26, 2024 | News
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces that the United States (U.S.) Food and Drug Administration (FDA) has...
July 24, 2024 | News
Everest Medicines, a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeuti...
July 18, 2024 | News
Biosyngen, a leading biotechnology company focused on the development of innovative cell therapies, recently announced that the Center for Drug Evaluation ...
July 17, 2024 | News
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel Nectin-4 targeting ADC (R&D code: 9MW2821)...
July 16, 2024 | News
IND for clinical study for combination therapy with hormone therapy in prostate cancer patients to be submitted in August, 2024. Niclosamide-based metab...
July 12, 2024 | News
LEQEMBI is now available for patients with mild cognitive impairment (MCI) or mild dementia, collectively referred to as early AD, the population in which ...
July 11, 2024 | News
- Following its initial approval for the treatment of relapsed/refractory multiple myeloma (R/R MM), XPOVIO® has now received approval as a monoth...
July 08, 2024 | News
Eleva, a pioneer in unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform, announced today that the European Commis...
July 04, 2024 | News
The European Commission (EC) has authorized the marketing of OBGEMSA™ (vibegron) by Pierre Fabre Laboratories for the symptomatic treatment of overac...
July 01, 2024 | News
- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treat...
June 27, 2024 | News
Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group (2096.HK), announced that Enlituo® (generic name: cetu...
June 27, 2024 | News
— Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial — — FRUZ...
June 24, 2024 | News
Sarepta Therapeutics, the leader in precision genetic medicine for rare diseases, today announced U.S. Food and Drug Administration (FDA) approv...
June 21, 2024 | News
Most Read
Bio Jobs
News
Editor Picks